-
Tytuł:
-
Therapy-related, mixed phenotype acute leukemia with t(1;21)(p36;q22) and RUNX1 rearrangement.
-
Autorzy:
-
Yamamoto K; Department of Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Japan. />Sada A
Kawano Y
Katayama Y
Shimoyama M
Matsui T
-
Źródło:
-
Cancer genetics and cytogenetics [Cancer Genet Cytogenet] 2010 Sep; Vol. 201 (2), pp. 122-7.
-
Typ publikacji:
-
Case Reports; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [New York] Elsevier/North-Holland.
-
MeSH Terms:
-
Chromosomes, Human, Pair 1*
Chromosomes, Human, Pair 21*
Gene Rearrangement*
Core Binding Factor Alpha 2 Subunit/*genetics
Leukemia, Myeloid, Acute/*genetics
Neoplasms, Second Primary/*genetics
Adult ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Fatal Outcome ; Flow Cytometry ; Humans ; Immunophenotyping ; In Situ Hybridization, Fluorescence ; Karyotyping ; Leukemia, Myeloid, Acute/chemically induced ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Neoplasms, Second Primary/chemically induced ; Neoplasms, Second Primary/diagnosis
-
Substance Nomenclature:
-
0 (Antineoplastic Agents)
0 (Core Binding Factor Alpha 2 Subunit)
0 (RUNX1 protein, human)
-
Entry Date(s):
-
Date Created: 20100805 Date Completed: 20100903 Latest Revision: 20100804
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.cancergencyto.2010.05.011
-
PMID:
-
20682397
-
We describe here a new case of therapy-related acute leukemia with t(1;21)(p36;q22). A 25-year-old man was admitted because of anemia and thrombocytopenia. Four years before, he had received combination chemotherapy including etoposide for seminoma. Bone marrow was hypercellular, with 49% myeloperoxidase (MPO) staining-negative blasts. Chromosome analysis showed 46,XY,t(1;21)(p36.3;q22)[11]/49,sl,+8,+16,+20[9]. Fluorescence in situ hybridization demonstrated that RUNX1 signals at 21q22 were split onto the der(1)t(1;21) and der(21)t(1;21). Immunophenotypic analyses revealed that blasts were positive for CD19, CD79a, and cytCD22, as well as MPO, CD13, and CD33, fulfilling the diagnostic criteria of mixed phenotype acute leukemia, B/myeloid. The patient died of disease progression after 10 months. Thus, acute leukemia with t(1;21) and RUNX1 rearrangement could be associated with B/myeloid mixed phenotype as well as previous topoisomerase II inhibitor therapy and poor prognoses.
(2010 Elsevier Inc. All rights reserved.)